Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market, threatening the position of both LAMAs and LABAs / inhaled corticosteroids (ICSs). Because of the progressive and irreversible nature of COPD, many patients eventually require more-aggressive treatment and are prescribed a combination of a LABA, a LAMA, and an ICS, providing a market opportunity for the triple-therapy combinations (e.g., Trelegy). The launch and uptake of generic versions of blockbuster inhaled drugs (e.g., salmeterol / fluticasone and albuterol sulfate) increases the affordability of treatment, further changing prescribing patterns.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Mylan, Sunovion, Teva
Key drugs: albuterol sulfate HFA, ProAir HFA, Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Incruse, Lonhala, Spiriva, Yupelri, Anoro, Bevespi, Stiolto, Combivent, Pulmicort, Brovana, Daliresp, Trelegy